瑞舒伐他汀钙片对冠心病合并心力衰竭患者的治疗效果

目的探讨瑞舒伐他汀钙片对冠心病合并心力衰竭患者的血脂指标、心功能与炎症因子水平的影响。方法80例冠心病合并心力衰竭患者,依据药物治疗方案不同分为对照组和实验组,每组40例。对照组接受基础药物方案治疗,实验组在对照组治疗基础上给予瑞舒伐他汀钙片治疗。比较两组患者治疗前后的血脂总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平、心功能指标左室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、左室收末缩期内径(LVESD)]以及炎症因子超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、脑钠肽(BNP)]水平。结果治疗后,实验组患者TC(4.74±0.55)mmol/L、TG(1.23±0.21)mmol/L、HDL-C(3.98±0.55)mmol/L均明显低于对照组的(5.97±0.84)、(1.86±0.42)、(5.02±0.46)mmol/L,LDL-C(1.83±0.33)mmol/L高于对照组的(1.33±0.26)mmol/L;实验组患者LVEDD(50.53±4.66)mm、LVEF(56.62±4.67)%、LVESD(37.28±3.24)mm均优于对照组的(59.23±6.72)mm、(49.23±5.01)%、(40.28±3.08)mm;实验组患者Hs-CRP(6.31±0.53)mg/L、TNF-α(153.23±12.12)ng/L、BNP(557.34±36.45)μg/L均低于对照组的(8.82±0.55)mg/L、(287.32±21.21)ng/L、(892.53±42.44)μg/L。差异均具有统计学意义(P<0.05)。结论冠心病合并心力衰竭患者接受瑞舒伐他汀钙片治疗,有助于其血脂指标、心功能和炎症因子的调节,因而应用价值较高。

Therapeutic effect of rosuvastatin calcium tablets on patients with coronary heart disease and heart failure

Objective To discuss the effect of rosuvastatin calcium tablets on blood lipid index,cardiac function and inflammatory factors of patients with coronary heart disease and heart failure.Methods A total of 80 patients with coronary heart disease and heart failure were divided into control group and experimental group according to different medications,with 40 cases in each group.The control group received basic drug treatment,and the experimental group received rosuvastatin calcium tablets on the basis of the control group.The blood lipidtotal cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C)]levels,heart function indicatorsleft ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF),left ventricular end systolic diameter(LVESD)]and inflammatory factorhigh-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),brain natriuretic peptide(BNP)]levels before and after treatment were compared between the two groups.Results After treatment,TC(4.74±0.55)mmol/L,TG(1.23±0.21)mmol/L and HDL-C(3.98±0.55)mmol/L of the experimental group were obviously lower than(5.97±0.84),(1.86±0.42)and(5.02±0.46)mmol/L of the control group,and LDL-C(1.83±0.33)mmol/L was higher than(1.33±0.26)mmol/L of the control group;LVEDD(50.53±4.66)mm,LVEF(56.62±4.67)%and LVESD(37.28±3.24)mm of the experimental group were better than(59.23±6.72)mm,(49.23±5.01)%and(40.28±3.08)mm of the control group;hs-CRP(6.31±0.53)mg/L,TNF-α(153.23±12.12)ng/L and BNP(557.34±36.45)μg/L of the experimental group were lower than(8.82±0.55)mg/L,(287.32±21.21)ng/L and(892.53±42.44)μg/L of the control group.The difference was statistically significant(P<0.05).Conclusion Rosuvastatin calcium tablets is helpful to the regulation of blood lipid index,cardiac function and inflammatory factors of patients with coronary heart disease complicated with heart failure,so it has high practical value.